Academic Journal
Integration of single‐cell and bulk transcriptomics reveals the association of manganese metabolism‐related genes with prognosis and immune infiltration in lung adenocarcinoma.
| Τίτλος: | Integration of single‐cell and bulk transcriptomics reveals the association of manganese metabolism‐related genes with prognosis and immune infiltration in lung adenocarcinoma. |
|---|---|
| Συγγραφείς: | Li, Hongliang, Wei, Shuzhen, Li, Wei, Sun, Junxia, Wang, Yi |
| Πηγή: | Clinical & Translational Immunology; Mar2026, Vol. 15 Issue 3, p1-20, 20p |
| Θεματικοί όροι: | Manganese, Prognosis, Biomarkers, RNA sequencing, Transcriptomes, Antineoplastic agent development, Lung tumors, Tumor-infiltrating immune cells |
| Περίληψη: | Background: Lung adenocarcinoma (LUAD) is associated with a poor prognosis. Manganese metabolism plays a critical role in antitumor immunity. The prognostic significance of manganese metabolism–related genes (MRGs) in LUAD remains unclear. Methods: Single‐cell RNA sequencing and TCGA transcriptomic data were integrated to identify expressed MRGs. Cell subpopulations were defined using AUCell scoring. A prognostic signature was constructed using univariate Cox regression, LASSO regression and multivariate Cox analysis. A nomogram incorporating the manganese metabolism–related risk score (MRS) and clinical variables was developed, and predictive performance was evaluated using receiver operating characteristic curves. Immune infiltration patterns and drug sensitivity were further analysed. Results: A robust prognostic model based on nine genes, including KLRF1, demonstrated strong predictive performance. Patients in the high‐MRS group exhibited increased M1 macrophage infiltration and shorter overall survival, whereas the low‐MRS group was characterised by enrichment of resting dendritic cells. Drug sensitivity analyses suggested that JQ1 and Vorinostat may be more effective in low‐MRS patients, while Pevonedistat and LCL161 may be preferable for high‐MRS patients. In vitro experiments confirmed that high PTMA expression promoted malignant phenotypes in LUAD cells, and that combined JQ1 treatment and PTMA knockdown exerted synergistic antitumor effects. Conclusions: We established and validated a prognostic signature based on nine MRGs. The synergistic antitumor effects of JQ1 and PTMA suppression were verified. This model provides a novel biomarker framework and therapeutic guidance for prognostic assessment and personalised treatment in LUAD. [ABSTRACT FROM AUTHOR] |
| Copyright of Clinical & Translational Immunology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Βάση Δεδομένων: | Complementary Index |
καταχωρήστε σχόλιο πρώτοι!